Traders should await the full filing disclosure to assess any potential impact on corporate governance, board composition, or shareholder initiatives. Monitor for subsequent filings or press releases from PCRX regarding the upcoming vote.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 12 $23.53entry
- T+1 · 8mo ago −1.15%α −0.55% · $23.26
- T+5 · 8mo ago −4.08%α −3.10% · $22.57
- T+20 · 7mo ago +1.10%α −0.87% · $23.79
- T+60 · 5mo ago −3.31%α −14.01% · $22.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Analysis based on filing metadata only, document content was unavailable. This DEFA14A filing for Pacira BioSciences, Inc. (PCRX) likely relates to proxy materials for an upcoming shareholder meeting, possibly involving director elections, executive compensation, or other corporate governance matters. Without access to the actual filing content, no specific developments or financial impacts can be assessed.
Key Facts
- Filing type is DEFA14A, indicating supplemental proxy materials were submitted ahead of a shareholder meeting.
- Such filings typically include updates or revisions to previously filed proxy statements, such as changes in board recommendations, additional proposals, or responses to shareholder inquiries.
- No document content is available to determine specific agenda items, activist involvement, or management positions.
Financial Impact
Not specified
Risk Factors
- Material developments, such as an activist campaign or contested board election, cannot be ruled out but are unconfirmed due to missing document content.
- Delayed access to proxy details may limit ability to anticipate shareholder sentiment or voting outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers